Table 1. Main data from unplanned subgroup analyses from the three placebo-controlled Phase III trials of regorafenib, cabozantinib and ramucirumab in second line post-sorafenib.
| Regorafenib10 (n = 573) | Cabozantinib11 (n = 707) | Ramucirumab12 (n = 292) | |
|---|---|---|---|
| OS: HR (95% CI) | 0.63 (0.50–0.79) | 0.76 (0.63–0.92) | 0.74 (0.56–0.99) |
| Males/females | ++/+ | ++/+ | ++/- |
| Age: </> 65 years | ++/+ | +/++ | +/++ |
| PS 0/1 | ++/+ | ++/+ | +/+ |
| Asia/West | ++/++ | 0/++ | +/+ |
| HBV: yes | ++ | ++ | + |
| HCV: yes | + | - | + |
| AFP: low/high | ++/++ | +/++ | -/++ |
| MVI: yes/no | ++/++ | +/+ | (-)/++ |
| EHS: yes/no | ++/0 | ++/0 | ++/+ |
EHS: Extrahepatic spread; HBV: Hepatitis B virus infection; HCV: Hepatitis C virus infection; HR: Hazard ratio; MVI: Macroscopic venous invasion; OS: Overall survival; PS: Performance status.